logo
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Business Upturn06-05-2025

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.
All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores.
TSPO-PET imaging showed significant reductions in microglial activation at six months (p<0.05).
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ('Tiziana' or the 'Company'), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced promising results from an open-label clinical study evaluating nasal foralumab, the world's only fully human anti-CD3 monoclonal antibody administered intranasally, for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS). This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial activation, and stabilized clinical progression in patients suffering from progression independent of relapse activity (PIRA)—a major unmet need in the treatment of MS, and a key disease endpoint for intranasal foralumab development. The article is titled 'Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS.' This study is the first to integrate, F18TSPO PET, Proteomics, and Clinical assessments in na-SPMS. These findings in MFIS score reduction are a critically important Quality of Life (QoL) measure for patients with MS.
Study Highlights: Ten patients with na-SPMS, who continued to progress despite B-cell therapy, were treated with nasal foralumab for a minimum of six months.
No serious or severe treatment-related adverse events were reported.
All patients experienced stabilization of their Expanded Disability Status Scale (EDSS) scores; three of four patients that were treated continuously for 12 months showed improvement.
Fatigue, a major symptom burden in MS, improved in six out of ten patients, as measured by the Modified Fatigue Impact Scale (MFIS).
Total MFIS scores correlated strongly with mGALP scores in the hippocampus (r=0.89, p=0.007) at baseline.
No new T2 lesions were observed on MRI.
TSPO-PET imaging showed significant reductions in microglial activation at six months (p<0.05).
Single-cell RNA sequencing revealed early and sustained changes in peripheral immune cells, including increased regulatory T cells (Tregs) and expression of TGFβ across multiple cell types.
'Our findings mark a significant advancement for patients living with non-active Secondary Progressive MS, who currently have very limited treatment options,' said Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School and senior neurologist at Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System. 'Nasal administration of foralumab represents a novel, non-invasive approach that not only induces regulatory immunity but also reduces harmful CNS inflammation.'
PIRA and progressive forms of MS are characterized by central nervous system-centric inflammation driven by microglial activation, processes not adequately addressed by existing therapies. Traditional MS treatments targeting B-cells and cell trafficking have limited efficacy in managing progression behind the blood-brain barrier.
Nasal foralumab leverages the mucosal immune system to induce regulatory immune responses, offering a novel mechanism to suppress CNS inflammation without the systemic immunosuppression seen with intravenous therapies. Previous studies showed that nasal anti-CD3 could treat progressive MS in animal models by expanding LAP+ and IL-10+ Tregs, providing the scientific rationale for this human study.
In parallel with these encouraging results, Tiziana Life Sciences has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial to further assess the efficacy and safety of nasal foralumab in a larger cohort of patients with na-SPMS. This trial is expected to reach top line data read out at the end of 2025.
'We are incredibly excited by these results, which validate the potential of nasal foralumab to fundamentally shift the treatment paradigm for progressive MS,' said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. 'We are also committed to advancing this promising therapy into other larger clinical studies, such as Alzheimer's Disease and ALS as quickly as possible.'
This article has been submitted for peer review, and the full preprint is available here: https://www.medrxiv.org/content/10.1101/2025.04.30.25326602v1
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Tiziana's Annual Report on Form 20-F for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences LtdPaul Spencer, Business Development, and Investor Relations+44 (0) 207 495 2379
email: [email protected]

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ColonBroom GLP-1 Booster Website Updated to Highlight Daily Supplement for Metabolic Health
ColonBroom GLP-1 Booster Website Updated to Highlight Daily Supplement for Metabolic Health

Yahoo

time2 hours ago

  • Yahoo

ColonBroom GLP-1 Booster Website Updated to Highlight Daily Supplement for Metabolic Health

New website update showcases natural GLP-1 support supplement designed to curb cravings, support metabolism, and promote healthy weight management SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) -- ColonBroom, a U.S.-based wellness brand, has announced a new update to its official website to highlight the launch of ColonBroom GLP-1 Booster—a daily supplement formulated to support metabolic function, appetite regulation, and overall weight wellness. Now available across the United States, the product offers a natural, lifestyle-friendly solution backed by science-supported ingredients. According to the official product website ( ColonBroom GLP-1 Booster is designed to work alongside the body's internal systems by promoting satiety, curbing cravings, and supporting blood sugar balance. The formula targets key wellness goals like reducing excess visceral fat and helping users manage weight more effectively without relying on restrictive diets or intense routines. 'ColonBroom GLP-1 Booster reflects our mission to simplify wellness with natural tools that align with modern lifestyles,' said a company spokesperson. 'This formula is designed with purpose—combining evidence-backed ingredients for those seeking real metabolic support.' The formulation includes Berberine, Chromium Picolinate, 5-HTP, Saffron Extract, and Bupleurum Root Extract—ingredients selected for their known roles in supporting GLP-1 activity, blood sugar balance, mood regulation, and fat metabolism. ColonBroom confirms that all supplements are manufactured in facilities that adhere to rigorous quality and safety protocols. The brand offers a satisfaction guarantee for new customers and invites visitors to explore ingredient insights, customer FAQs, and personalized quiz recommendations directly on the website. About ColonBroom ColonBroom is a San Francisco-based wellness brand dedicated to creating clean, effective, and easy-to-use daily supplements. With a focus on transparency and science-backed simplicity, ColonBroom empowers adults to take proactive steps toward digestive and metabolic wellness. Product and Contact Information Brand: ColonBroomWebsite: hello@ (Order Support): 1-888-505-0855Mailing Address: 505 Montgomery Street, 10th & 11th Floors, San Francisco, California, 94111, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: hello@ Phone (Order Support): 1-888-505-0855Sign in to access your portfolio

ROOH Officially Opens in Toronto With Focus on Health-Conscious Indian Cuisine
ROOH Officially Opens in Toronto With Focus on Health-Conscious Indian Cuisine

Business Upturn

time2 hours ago

  • Business Upturn

ROOH Officially Opens in Toronto With Focus on Health-Conscious Indian Cuisine

ROOH has officially launched in downtown Toronto, offering a health-focused Indian dining experience centered on nutrition, sustainability, and regional flavors. The new restaurant builds on Bar Goa's model by applying research-based cooking and transparent sourcing to modern fine dining. Photo Courtesy of ROOH TORONTO, June 10, 2025 (GLOBE NEWSWIRE) — ROOH has opened its doors at 633 College Street in Toronto, offering a menu centered on sustainability, nutrition, and regionally inspired Indian flavors. The restaurant represents the second concept from the team behind Bar Goa, recognized in the 2024 Michelin Guide. ROOH offers a distinct alternative to traditional Indian dining by combining public health principles with acceptable dining practices. The venue features a seasonally adjusted menu built around transparent sourcing and scientific cooking practices to preserve nutrients and support long-term wellness. The kitchen team follows structured methods informed by behavioral science and nutritional research. Staff receive ingredient sourcing, food science, and guest communication training, supporting the restaurant's broader mission to connect hospitality with public health goals. ROOH expands on Bar Goa's health-forward model by drawing from culinary traditions across India. The menu features seasonal vegetables, fermented ingredients, and spice blends supported by nutrition studies. The team develops dishes by drawing on regional culinary research and partnering with local ingredient suppliers. 'We apply food science alongside tradition to raise the profile of regional Indian cuisine,' says founder Dr. Jayadeep Patra. 'This method offers a new take that fits today's changing dining scene.' The restaurant's model responds to increasing demand for meals combining rich flavor and wellness alignment. ROOH's operational structure reflects a long-term vision to integrate evidence-based practices into modern dining experiences. Together with its sister restaurant, Bar Goa, ROOH continues to evolve a food philosophy rooted in sustainability, science, and culturally grounded cuisine. About ROOH and Bar Goa ROOH and Bar Goa are Indian fine-dining restaurants based in Toronto. They were built on the work of public health scientist and restaurateur Dr. Jayadeep Patra. The Michelin Guide recognized Bar Goa in 2024 for its health-conscious coastal Indian cuisine. ROOH builds on this model by offering seasonal, regional Indian dishes shaped by nutritional research and sustainability practices. Both restaurants highlight transparency, ingredient integrity, and a hospitality approach informed by science. Contact information: Contact Person's Name: Dr. Jayadeep Patra Organization / Company: ROOH and Bar Goa Company website: | Contact Email Address: [email protected] City, Province, Country: 633 College St, Toronto, Ontario, Canada A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Enhance.MD Launches Nationwide Telehealth Expansion to Support Men's Hormonal Health and Medically Supervised Weight Loss
Enhance.MD Launches Nationwide Telehealth Expansion to Support Men's Hormonal Health and Medically Supervised Weight Loss

Business Upturn

time2 hours ago

  • Business Upturn

Enhance.MD Launches Nationwide Telehealth Expansion to Support Men's Hormonal Health and Medically Supervised Weight Loss

San Diego, June 10, 2025 (GLOBE NEWSWIRE) — a U.S.-based telehealth provider specializing in men's hormonal optimization and metabolic wellness, has officially expanded its clinical care services nationwide. This expansion supports a growing number of men seeking personalized healthcare solutions for low testosterone, weight challenges, and performance-related health issues—all from the convenience of their own home. Through its secure platform, connects patients to licensed U.S. physicians who evaluate medical history, review lab work, and prescribe clinically appropriate treatment programs. The company's services now reach patients in all 50 states, including those in remote or underserved areas where access to specialized care may be limited. 'Our mission is to make medically supervised hormone therapy and weight loss care more accessible for men everywhere,' said a spokesperson for 'This nationwide expansion reflects our commitment to safe, evidence-based telemedicine that empowers patients to take charge of their long-term health.' virtual platform is designed for ease of use, featuring: Fast, secure medical intake and scheduling Lab partnerships for at-home or local diagnostic testing Ongoing provider monitoring and patient support HIPAA-compliant communication channels Nationwide medication delivery where legally permitted All care is provided by board-certified physicians and licensed healthcare professionals who follow strict clinical guidelines. Treatment options may include testosterone replacement therapy (TRT), GLP-1-based metabolic weight programs, and supportive interventions for men's health, always following a personalized and physician-reviewed protocol. With recent updates to its website and mobile user interface, has also improved patient onboarding, reduced consultation wait times, and expanded clinical support availability. About is a telehealth company focused on optimizing men's health through medical evaluation, diagnostic testing, and customized treatment plans. The company specializes in testosterone therapy, weight management, and performance-focused wellness protocols—delivered entirely online through licensed U.S. providers. By combining technology with medical oversight, empowers men to pursue health goals with professional guidance and national reach. Contact: [email protected] 8:00 AM – 8:00 PM EDT Monday – Friday9:00 AM – 5:00 PM EDT Saturday – Sunday16776 Bernardo Center Dr. Suite 203, San Diego, CA 92128

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store